Statistik Asas
| CIK | 1366581 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tian'an Pharmaceutical Co., Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| December 17, 2018 |
TNPH / Tian'an Pharmaceutical Co., Ltd. AW Form RW/A December 17, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| December 4, 2018 |
TNPH / Tian'an Pharmaceutical Co., Ltd. RW Form RW December 4, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| November 21, 2018 |
TNPH / Tian'an Pharmaceutical Co., Ltd. 15-15D OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: May 31, 2021 Estimated average burden hours per response 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF |
